Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Feb;26(1):65-71.
doi: 10.1177/1533317510391240.

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease

George Grossberg  1 , Xiangyi Meng, Jason T Olin
Affiliations
Randomized Controlled Trial

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease

George Grossberg et al. Am J Alzheimers Dis Other Demen. 2011 Feb.

Abstract

Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer's disease (AD).

Methods: Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm(2)]), rivastigmine capsules (6 mg twice daily), or placebo, and impact on activities of daily living (ADLs) was assessed utilizing 3 subscales: basic, high-level function, and autonomy.

Results: At week 24, both rivastigmine groups demonstrated significantly superior performance in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score versus placebo (rivastigmine patch, P = .013; capsules, P = .039). Overall, both rivastigmine formulations provided benefits in ADL subscales. For basic ADLs, rivastigmine capsules performed significantly better than placebo (P = .012). For high-level function ADLs, rivastigmine patch performed better than placebo (P = .056). For autonomy ADLs, rivastigmine patch performed significantly better than placebo (P = .017).

Conclusion: Rivastigmine patches and capsules provide significant effects in both total and subscale ADLs in patients with probable AD.

PubMed Disclaimer

References

    1. Cummings JL, Koumaras B., Chen M., Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005;3(3):137-148. - PubMed
    1. Andersen CK, Wittrup-Jensen KU, Lolk A., Andersen K., Kragh-Sorensen P. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes. 2004;2:52. - PMC - PubMed
    1. Exelon Capsule. Prescribing Information. 2001. http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf . Accessed July, 2010.
    1. Exelon transdermal patch. Prescribing information. 2007. http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf. Accessed July, 2010.
    1. Corey-Bloom J., Anand R., Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease . Int J Geriatr Psychopharmacol. 1998;1(1):55-65.

Publication types

MeSH terms